SCHEMBL1872138

SCHEMBL1872138

O=C(O)N1CCC(=Cc2cc(F)c([N+](=O)[O-])cc2Cl)CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.39
USP14 P54578 1/20 0.39
UCHL5 Q9Y5K5 1/20 0.39
SRD5A2 P31213 4/20 0.37
SMN1; SMN2 Q16637 5/20 0.35
LMNA P02545 4/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 4/20 0.34
ALDH1A1 P00352 3/20 0.34
GAA P10253 2/20 0.34
HTT P42858 2/20 0.34
MITF O75030 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HRH4 Q9H3N8 1/20 0.33
MAPK1 P28482 1/20 0.33
GPR174 Q9BXC1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1865742 0.89 SRD5A2 (0.41) CASP3USP14UCHL5SRD5A2SMN1; SMN2
SCHEMBL1870418 0.84 MAPT (0.42) SMN1; SMN2LMNAKMT2AMEN1MAPT
SCHEMBL22556898 0.81 MAPT (0.39) CASP3USP14UCHL5SRD5A2SMN1; SMN2
SCHEMBL1863164 0.79 CASP3 (0.47) CASP3USP14UCHL5SRD5A2SMN1; SMN2
SCHEMBL1866587 0.74 SRD5A2 (0.40) CASP3USP14UCHL5SRD5A2LMNA
SCHEMBL5347699 0.73 ERN1 (0.53) SMN1; SMN2LMNAL3MBTL1KMT2AMEN1
SCHEMBL1869807 0.73 MAPT (0.45) CASP3USP14UCHL5SMN1; SMN2LMNA
SCHEMBL15537076 0.73 SRD5A2 (0.51) SRD5A2SMN1; SMN2KMT2AMAPTALDH1A1
SCHEMBL22556714 0.72 TSHR (0.47) SMN1; SMN2LMNAL3MBTL1KMT2AMEN1
SCHEMBL6822675 0.72 CASP3 (0.41) CASP3USP14UCHL5SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108939-B2 (1, 1, 1,3,3,3-hexafluoro-2 hydroxypropan-2-yl) phenyl derivative, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME B.V. (NL) 2015-08-18 US disclosed
EP-2493855-B1 (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME (NL) 2014-02-26 EP disclosed
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2012-09-20 US disclosed
EP-2493855-A1 (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS MSD Oss B.V. (NL) 2012-09-05 EP disclosed
WO-2011051282-A1 (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS TGFB1, FPR1, TGFB2 CASP3 922/4885USP14 2366/4885UCHL5 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.